A
AdoRx Therapeutics
Adenosine pathway modulators for cancer immunotherapy
About AdoRx Therapeutics
AdoRx Therapeutics is a UK-based drug discovery company established in 2017, focusing on the development of new cancer therapeutics. The company’s core strategy is to modulate the adenosine pathway to counteract cancer's ability to evade the immune system. High concentrations of adenosine in the tumor microenvironment suppress immune responses; AdoRx aims to overcome this by designing and developing fit-for-purpose adenosine receptor antagonists.
AdoRx was founded by healthcare investor Epidarex Capital and is led by a team of veterans from the pharmaceutical industry. The leadership team, including CEO Pete Finan, former head of the Novartis Institutes of BioMedical Research UK site, Dr. Clive McCarthy, and Dr. Roy Pettipher, collectively holds extensive experience, having advanced over twenty-five drug candidates into clinical development. The company operates on a research and development model, financed through venture capital and strategic partnerships. In June 2018, AdoRx announced an initial funding round of $10 million from investors Epidarex Capital and the CRT Pioneer Fund.
A significant milestone was achieved in February 2019, when AdoRx entered a strategic collaboration with Johnson & Johnson Innovation and its Lung Cancer Initiative. This partnership granted an exclusive option to research, develop, and commercialize novel antagonists from AdoRx's portfolio for lung cancer treatment. The company's product pipeline is in the pre-clinical stage and includes antagonists for the Adenosine A2A receptor and dual-blockade antagonists for A2A/A2B receptors.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 26.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2018 | $10M | $40M | Epidarex Capital · Sixth Element Capital · Oxford University Innovation | ↗ |
Growth signals
Latest recorded traffic for AdoRx Therapeutics is 100 monthly website visits, down 84.4% over the last three months. AdoRx Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
SpireaAdvanced antibody-drug conjugate technology for cancer therapeutics |
Harrogate, United Kingdom | Operational | 8 | $3.8M | $13M |
Curileum DiscoveryNovel therapeutics correcting cell production in gut mucosa |
London, United Kingdom | Operational | |||
DJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases |
Oxford, United Kingdom | Acquired | |||
Argonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation |
Oxford, United Kingdom | Acquired | |||
FemtogenixDNA-interactive payloads for antibody-drug conjugates |
St Albans, United Kingdom | Operational | |||
Oxford VacmedixDevelop therapeutic agents for the treatment of cancer |
Oxford, United Kingdom | Operational | |||
AutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases |
London, United Kingdom | Operational | |||
Kuur TherapeuticsManufactures cellular immunotherapeutics in order to treat cancer and infectious diseases |
Houston, United States | Acquired |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AdoRx Therapeutics in the Edinburgh ecosystem
The AdoRx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Epidarex Capital- SCSixth Element Capital
Oxford University Innovation
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about AdoRx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AdoRx Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









